Prevalence and Characterization of Neuropathic Pain in a Primary-Care Setting in Spain
- 172 Downloads
Background and objective: Different studies have shown pain to be one of the most frequent causes of health-care resource utilization, and a major public health concern because of its social repercussions. In Spain there are no recent data on the prevalence and management of neuropathic pain in the general primary-care setting. This study aimed to gain epidemiological insight into neuropathic pain in the Spanish primary-care setting.
Methods: This was a cross-sectional, one-day, multicentre, observational epidemiological study involving 623 primary-care physicians in Spain. Patients who experienced pain were classified into three groups: pure neuropathic pain, mixed neuropathic pain or nociceptive pain. Pain intensity was evaluated on a visual analogue scale (VAS), range 0–10. Information on the location, duration, aetiology and current treatment of pain was obtained, together with data on whether the patients were referred to specialized care and to which type of specialist.
Results: In a single day, 23 529 patients received primary care, and of these, 7220 experienced pain (30.7% [95% CI 29.5, 31.7]). Patients with pure neuropathic pain comprised 11.8% (95% CI 10.5, 13.2) of the 3044 patients for whom pain was the reason for consultation and the type of pain was documented, patients with mixed neuropathic pain accounted for 13.4% (95% CI 12.0, 14.8) of this group, and patients with nociceptive pain for 74.9% (95% CI 73.1, 76.7). Patients with pure neuropathic pain mostly received exclusively pharmacological treatment (84.6% [95% CI 80.3, 89.0]), with anti-epileptic drugs being the most widely used substances (52.5% [95% CI 47.3, 57.7]), followed by non-opioid analgesics (35.2% [95% CI 30.2, 40.1]) and NSAIDs (26.8% [95% CI 22.2, 31.4]). The mean duration of neuropathic pain was 11.7±23.3 months. The mean pain intensity on the VAS exceeded 6 in all groups. Over half of the patients were diagnosed in the primary-care centre, and a large proportion in turn were referred to a specialist, most frequently an orthopaedist.
Conclusion: The results of the present study show the high prevalence of neuropathic pain at the primary-care level in Spain. In addition, the data presented here point to a need to improve the management of outpatients with neuropathic pain in the Spanish primary-care setting, particularly in relation to the higher than recommended use of NSAIDs (which are not indicated for neuropathic pain) and the lower than recommended use of antiepileptic drugs with an analgesic indication for pain with a neuropathic component.
KeywordsNeuropathic Pain Trigeminal Neuralgia Nerve Entrapment Nociceptive Pain Regional Population Size
This study was supported by an unrestricted grant from Pfizer España (Pfizer Spain). Dr Pérez, Dr Saldaña and Dr Navarro have received honoraria from Pfizer as consultants. Dr Rejas is employed by Pfizer Spain. Inma Vilardaga is employed by the European Biometric Institute, a clinical research organization contracted by Pfizer to conduct the study. The authors wish to thank all the physicians who participated in the study for their contribution to the goals of study.
- 6.López-Silva MC, Sánchez de Enciso M, Rodríguez-Fernández MC, et al. Cavidol: de vida y dolor en atención primaria. Rev Soc Esp Dolor 2007; 14(1): 1–19Google Scholar
- 7.IASP Task Force in Taxonomy. Pain terms: a current list with definitions and notes on usage. In: Merksey H, Bogduk N, editors. Classification of chronic pain syndromes and definitions of pain terms. Seattle: IASP Press, 1994; 206–13Google Scholar
- 8.Saarto TWP. Antidepressants for neuropathic pain. Coch-rane Database Syst Rev 2005; (3): CD005454Google Scholar
- 9.Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev 2005(3):CD001133Google Scholar
- 19.Montero Homs J, Gutierrez-Rivas E, Pardo Fernandez J, et al. Epidemiological study of prevalence, incidence and neuropathic pain characterization in neurology units: Prevadol study. Neurologia 2005; 20: 385–9Google Scholar
- 20.Pardo J, Gutierrez-Rivas E, Montero J, et al. Estudio de prevalencia, adherencia farmacológica y calidad de vida en pacientes con dolor neuropático. Estudio Neuropathic. Neurología 2006; 21: 445–50Google Scholar